The buy side says: “He has become very aggressive in getting his ideas out onto the Street.”
For a sixth year in a row, Adam Feinstein of Barclays Capital captures the crown, thanks in part to his “brilliant and detailed analysis of what health care reform really means for these companies,” as one money manager puts it. Feinstein, 38, expanded his coverage universe last October to include medical-device manufacturers while continuing to highlight his long-term overweights on favorite names such as Universal Health Services; shares of the King of Prussia, Pennsylvania–based operator of specialty surgery centers rose 7.4 percent in the 12 months through August, compared with a 3 percent gain for the sector. Clients continue to profit from Feinstein’s buy rating on HCP, a Long Beach, California–based real estate investment trust that invests in health care facilities. First recommended way back in February 2008 and reiterated repeatedly since, HCP’s shares jumped 31.4 percent, from $26.80 to $35.22, in the year through August.
